Bruna Bárbara Mesquita de Almeida, Julia Miterhof Meirelles, Miriã da Silva Costa, Patrícia Aparecida da Cunha, Juliana Ribeiro Lucci
We don't know much about this study yet.
We're maintaining the world's largest resposity of hair loss
research. You can help out the community by
sending a PDF of this study here
.
Not sure how to get a study's PDF? You can email the authors
of the study.
A 26-year-old male started minoxidil treatment for male-pattern baldness and saw significant regrowth in three months. He is considering finasteride but is hesitant due to potential side effects.
The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.
Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.
Finasteride prescriptions in France now require an annual certificate acknowledging psychiatric and sexual risks, as the European Medicines Agency recognizes these risks. The conversation discusses the potential mental health effects of Finasteride, with some users reporting side effects and others questioning the statistical significance of these findings.
Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.
Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.